Pregnenolone sulfate (PREGS), one of the most abundantly produced neurosteroids in the mammalian brain, improves cognitive performance in rodents. The mechanism of this effect has been attributed to its allosteric modulatory actions on glutamate-and γ-aminobutyric acid-gated ion channels. Here we report a novel effect of PREGS that could also mediate some of its actions in the nervous system. We found that PREGS induces a robust potentiation of the frequency, but not the amplitude of miniature excitatory postsynaptic currents (mEPSCs) mediated by α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors in cultured hippocampal neurons. PREGS also decreased paired-pulse facilitation of autaptic EPSCs evoked by depolarization, indicating that it modulates glutamate release probability presynaptically. PREGS potentiation of mEPSCs was mimicked by dehydroepiandrosterone sulfate and (+)-pentazocine, but not by (-)-pentazocine, the synthetic (-) enantiomer of PREGS or the inactive steroid isopregnanolone. The σ receptor antagonists, haloperidol and BD-1063, blocked the effect of PREGS on mEPSCs, as did pertussis toxin and the membrane-permeable Ca 2+ chelator BAPTA-AM. These results suggest that PREGS increases spontaneous glutamate release via activation of a presynaptic G i/o -coupled σ receptor and an elevation in intracellular Ca 2+ levels. We postulate that presynaptic actions of neurosteroids have a role in the maturation and/or maintenance of synaptic networks and the processing of information in the central nervous system.
Introduction
In the 1980s, Baulieu and collaborators made the important discovery that certain steroids are synthesized in the central and peripheral nervous systems (1) . These compounds, known as neurosteroids, are produced locally in glial and neuronal cells and can exert important modulatory actions in the nervous system. A particularly abundant neurosteroid in the central nervous system is pregnenolone sulfate (PREGS) (1, 2) .
Although the neurophysiological role of endogenous PREGS has yet to be conclusively established, experiments involving exogenous administration of this compound suggest that it has a promnesic effect (3) (4) (5) (6) (7) . For example, post-training injection of PREGS into the hippocampus and amygdala of mice improves retention for foot-shock active avoidance training (4) . In addition, low levels of PREGS in the hippocampus were found to be correlated with a deficiency in cognitive performance in aged rats, which could be ameliorated by intra-hippocampal injections of this neurosteroid (5) . More recently, it was demonstrated that PREGS attenuates amyloid peptide-induced amnesia in mice (8) . Thus, PREGS or its analogs could potentially be used for the treatment of Alzheimer's disease and other neuropsychiatric disorders.
Although the mechanisms by which PREGS produces cognitive effects are not fully understood, numerous studies suggest that this agent modulates several neuronal ion channels (9) . For instance, PREGS has been shown to inhibit γ-aminobutyric acid-type A (GABA A ) receptors (10) , to potentiate N-methyl-D-aspartate (NMDA) receptors (11) (12) (13) (14) and to inhibit voltage-gated Ca 2+ channels (15). In addition to ion channels, PREGS has also been shown to target metabotropic receptors, such as σ receptors. These receptors were initially thought to belong to the opioid family of receptors, but are now categorized separately (16) . Two classes of pharmacologically defined σ receptors are widely accepted and are denoted as the σ 1 and σ 2 subtypes (16) . σ 1 receptors bind (+)-benzomorphans and haloperidol with high affinity. In contrast, σ 2 receptors bind haloperidol and (+)-benzomorphans with low affinity, and they also bind benzomorphans without enantioselectivity.
σ ligand binding sites can be detected both intracellularly on the endoplasmic reticulum (ER) and extracellularly on the plasma membrane (17) . A σ ligand-binding protein has recently been cloned from a number of tissues, including brain (18) . This binding protein exhibits the pharmacological profile of σ 1 receptors and is expressed in the ER (19) (20) (21) (22) (23) . Although its sequence has no known homology to other mammalian proteins, it shows similarity to the yeast sterol C 8 -C 7 isomerase involved in ergosterol biosynthesis (24) . Plasma membrane σ receptors can be activated by PREGS and other neurosteroids but, in contrast to σ ligand binding proteins expressed in the ER, appear to be directly coupled to pertussis-sensitive G proteins (25-28). Both the cDNA sequence and physiological role of these G proteincoupled metabotropic σ receptors have yet to be fully characterized.
In this paper, we report a novel effect of PREGS on glutamate release that depends on activation of plasma membrane σ receptors. Specifically, we measured the effects of this neurosteroid on miniature excitatory postsynaptic currents (mEPSCs) mediated by the α- spontaneous release of single presynaptic vesicles. It is well established that when a modulator affects presynaptic neurotransmitter release, it produces a change in the frequency, but not in the amplitude of miniature synaptic events (for instance, see (29) ). We found that PREGS selectively induces a robust increase in the frequency of mEPSCs, indicating that it enhances the probability of glutamate release from presynaptic terminals.
Moreover, we show that this effect depends on an elevation in intracellular Ca 2+ levels triggered by activation of presynaptic G i/o protein-coupled σ 1 ↑like receptors.
Experimental Procedures
Cell Culture. Animal procedures were approved by the Institutional Animal Care and Use Committee of the University of New Mexico Health Sciences Center and conform to National Institutes of Health guidelines. Neuronal cultures were prepared in all cases from postnatal day 3-4 Sprague-Dawley rats. These experiments utilized either mixed hippocampal cell cultures (prepared as described previously (30) ) or autaptic neuronal cultures grown on glial cells attached to collagen-on-agarose microislands (prepared as described elsewhere (31)). Neurons grown on microislands were used for the studies of paired-pulse facilitation (PPF). Neurons were used for electrophysiological experiments 8-14 days after culture.
Electrophysiology. Whole-cell patch-clamp experiments were performed using instrumentation and software previously described (30) , with the exception that mEPSCs were first recorded on digital audiotape and then digitized by using a Digidata 1200 interface and pClamp 7 software (Axon Laboratories, Foster City, CA). Miniature EPSCs were analyzed using the Mini Analysis Program from Synaptosoft (Decatur, GA). We recorded from pyramidal-like neurons that had large somas and well-defined dendritic processes. Neurons were clamped at -70 mV for most experiments and, when enantiomer of PREGS (ent-PREGS) has been described elsewhere (33 
Results
We first measured the effect of PREGS on mEPSCs to determine whether it modulated spontaneous glutamate release. To isolate AMPAR-mediated events, we recorded mEPSCs at 70 mV in 1 mM Mg 2+ -containing external solution. Under these conditions, CNQX (20 µM) reduced the frequency of events by 96 ± 3% (n = 7) with respect to control (data not shown). As illustrated in Fig 1, PREGS caused a robust, concentrationdependent, increase in mEPSC frequency. The effect of PREGS was significant at concentrations ≥ 10 µM (Fig. 1D ). The onset of this effect occurred within ~1 min after bath application of the neurosteroid and was fully reversible within ~2-4 min after washout. The increase in mEPSC frequency was observed at both 70 and 90 mV. At these membrane potentials, PREGS (50 µM) increased mEPSC frequency by 494 ± 184% (n=6) and 488 ± 192% (n =7), respectively (data not shown). This finding indicates that the effect of PREGS is not due simply to an increase in the detection of subthreshold mEPSCs. The effect of PREGS was also not due to NMDAR activation, because recording in Mg 2+ -free external solution containing the NMDAR antagonist AP5 (50 µM) had no effect on the action of this neurosteroid. PREGS (50 µM) increased mEPSC frequency by 448 ± 151% (n = 4) or 485
± 182% (n = 9) with respect to control in the presence of AP5 or Mg 2+ -containing external solution, respectively (data not shown). We did not detect any effect of PREGS on mEPSC amplitude at any of the concentrations examined; mEPSC amplitudes were changed by 1.6 ± 2.8%, 0.55 ± 3.6%, -1.6 ± 4.4% and -1.1 ± 3.5% with respect to control in the presence of 1, 10, 20 and 50 µM PREGS, respectively (see Fig 1C for an illustration of a lack of an effect of 20 µM PREGS). To eliminate the possibility of a nonspecific action and to determine the enantioselectivity of the PREGS effect, we tested the effect of the inactive neurosteroid, isopregnanolone, and the (-) enantiomer of PREGS, ent-PREGS, respectively. As shown (Fig. 1D ), these steroids did not induce a change in the frequency of mEPSCs. Since ent-PREGS has been shown to exert more potent U-shaped effects than PREGS under some experimental conditions (6), we also tested its effect at a 1 µM concentration and found that it does not affect mEPSC frequency (2.5 ± 0.9% change with respect to control; n=3).
To confirm that PREGS increases the probability of glutamate release, we measured its effect on PPF of autaptic AMPAR-mediated EPSCs evoked by depolarizing pulses (Fig 2) .
It is well established that manipulations that enhance the basal probability of release increase the impact of the first action potential (i.e. deplete synaptic vesicles), resulting in a reduction in PPF (For an example, see (34) ). Accordingly, we found that treatment with PREGS (50 µM) increases the amplitude of the first EPSC by 43 ± 11% (n =9; p<0.01 by one sample t test vs. a theoretical mean of zero; Fig 2A) and also reduces PPF (Fig 2B) , confirming that PREGS increases the probability of presynaptic glutamate release.
PREGS has been shown to inhibit NMDA receptor-dependent [ 3 H]-norepinephrine release
in hippocampal slices by a mechanism that involves σ 1 receptors (28). We therefore examined the role of these receptors on the effects of PREGS on glutamate release. As shown in Fig 3, the σ 1 receptor antagonists, haloperidol and BD-1063 (preincubation for 30-45 minutes at 37 0 C) blocked the PREGS-induced increase in mEPSC frequency.
Moreover, pretreatment with haloperidol or BD1063 did not affect the average basal frequency of mEPSCs (Fig. B1, C1 ). This finding indicates that the decrease in PREGS efficacy in the presence of these two compounds is not due to an overall decline in the spontaneous release probability. We next determined whether the effect of PREGS could be mimicked by other σ receptor agonists. We tested the effect of DHEAS, another neurosteroid that activates σ 1 -like receptors in the brain (25), and of (+)-pentazocine, the prototypical σ 1 receptor agonist. As shown in Fig 4, these compounds produced a similar increase in mEPSC frequency to that produced by PREGS (Fig 1D) . Conversely, (-)-pentazocine did not increase mEPSC frequency (Fig 1D) . None of these compounds significantly affected mEPSC amplitude (data not shown).
Plasma membrane σ receptors have been shown to be coupled to G i/o proteins (25-28).
Therefore, we tested the effect of pertussis toxin treatment on the PREGS-induced increase in mEPSC frequency. As illustrated in Fig 5, incubation of neurons for 36-48 hr at 37 o C with 50 ng/ml of pertussis toxin significantly reduced the effect of PREGS on mEPSC frequency. This result indicates that the effect of PREGS requires activation of the G i/o subtype of G proteins. As also shown, pretreatment with pertussis toxin did not affect basal frequency of mEPSCs (Fig. 5B ). This suggests that the decrease in PREGS efficacy in the presence of pertussis toxin is not due to an overall decline in the spontaneous release probability and is most likely due to a direct effect of pertussis toxin on the PREGSmediated second messenger cascades that result in increased spontaneous glutamate release.
σ receptors have been shown to regulate intracellular calcium (16, 35) and, therefore, we examined its role in the mechanism of action of PREGS. The results of these experiments are shown in Fig 6. As a control, neurons were first exposed to 50 µM PREGS, which produced the expected increase in mEPSC frequency. After washout, the same neurons were incubated for 15-20 min with the membrane permeable Ca 2+ chelator, BAPTA-AM (10 or 20 µM). A subsequent exposure to 50 µM PREGS failed to induce an elevation in mEPSC frequency (Fig 6A,B) . This result indicates that an elevation in intracellular Ca 2+ levels is required for the presynaptic actions of PREGS. To eliminate the possibility that the effect of BAPTA-AM was an artifact due to run down of the effect of PREGS, we applied PREGS twice under control conditions ( Fig 6C) . As shown, the effect of a second application of PREGS closely reproduced that of the first application (same result seen in 3 additional neurons).
Discussion

PREGS Increases Glutamate Release Probability:
In this paper, we report that PREGS induces a robust increase in the frequency, but not the amplitude of AMPAR-mediated mEPSCs in hippocampal neurons cultured from neonatal rats. Moreover, we found that PREGS reduces PPF of AMPAR-mediated synaptic responses, indicating that this neurosteroid increases the probability of glutamate release at the presynaptic level. To the best of our knowledge, this is the first report of a modulatory effect of PREGS on the basal probability of glutamate release in CNS neurons. It is noteworthy, however, that we previously found that PREGS exerts presynaptic modulatory actions on glutamatergic terminals in the rat hippocampus. Specifically, we demonstrated that PREGS enhances PPF of NMDAR-and AMPAR-mediated EPSPs in CA1 pyramidal neurons in hippocampal slices from adult rats (36) . Importantly, we did not find evidence indicating that PREGS affects the basal probability of glutamate release in these slices (36) .
Thus, PREGS appears to exert distinct effects on glutamate release depending on either the neuronal developmental stage or the type of neuronal preparation being used; i.e., it increases the probability of spontaneous glutamate release in hippocampal neurons cultured from neonatal rats and increases facilitation of evoked glutamate release in CA1 pyramidal neurons in hippocampal slices from adult rats.
Our finding that PREGS affects glutamate release contributes to the growing evidence that this neurosteroid has important regulatory actions on the release of a number of neurotransmitters. In agreement with the results of our study, in vivo microdialysis experiments have demonstrated that PREGS increases basal acetylcholine release in the hippocampus and cortex of rats (37) (38) (39) and that it also increases basal dopamine release in the rat nucleus accumbens (40) . Not all studies, however, have shown a potentiating effect of PREGS on basal neurotransmitter release. Teschemacher et al (41) found that PREGS (1-50 µM) reduces the probability of GABA release in cultured hippocampal neurons. Taken together with our finding that PREGS increases glutamate release in the same type of neurons, the results of Teschemacher et al (41) indicate that this neurosteroid differentially regulates basal neurotransmitter release from GABAergic versus glutamatergic axonal terminals. It should also be emphasized that another study found that PREGS (10 nM-3 µM) does not affect basal [ 3 H]-norepinephrine release in hippocampal slices from adult rats (28) . Thus, the effects of PREGS appear to depend on the neurotransmitter specificity of a particular presynaptic terminal.
Role of σ 1 ↑like Receptors in the Mechanism of Action of PREGS:
Monnet et al. (28) determined that PREGS decreases NMDA-evoked overflow of Consequently, our finding that the effect of PREGS on quantal glutamate release is blocked by pertussis toxin suggests that these G i -coupled metabotropic σ receptors mediate the actions of PREGS on glutamate release in cultured hippocampal neurons.
Our finding that PREGS increases mEPSC frequency at concentrations ≥10 µM is in agreement with the estimated binding affinity (~3 µM) of this neurosteroid for brain σ
receptors (42), although there is an apparent contradiction between our findings and the results of Ueda et al (25). These investigators reported that PREGS increases [ 35 S]-GTPγS
binding in brain homogenates in the 10 nM-10 µM range, which indicates that this neurosteroid has a more potent interaction with metabotropic σ receptors. However, the prefrontal cortex and amygdala of adult mice were used to prepare the homogenates for those studies and it is possible that higher concentrations of PREGS are required to activate metabotropic σ receptors in axonal terminals of developing hippocampal neurons. In these neurons, presynaptic metabotropic σ receptors could be associated with different proteins or could be regulated by posttranslational mechanisms that are only active during development.
It seems unlikely that the recently cloned σ binding protein is directly involved, at least initially, in the mechanism of the presynaptic actions of PREGS for several reasons (19) (20) (21) (22) (23) . First, the σ binding protein sequence contains an ER retention signal (18) and, therefore, PREGS would not be expected to be able to reach this intracellular protein in intact neurons because of its limited lipid solubility. Second, cloning of the σ binding protein revealed that it only has a single transmembrane domain, and also that it lacks a G protein binding domain (18) .
Therefore, our finding that the effect of PREGS is blocked by pertussis toxin treatment suggests that the σ binding protein is not involved in this process. conclude that a metabotropic receptor with the pharmacological profile of the σ 1 subtype mediates the actions of PREGS on the probability of glutamate release.
An important finding of our study is that ent-PREGS, the synthetic (-) enantiomer of PREGS, did not affect mEPSC frequency. This result indicates that the interaction between presynaptic σ 1 -like receptors and PREGS is enantioselective. This finding is not surprising given that the action of pentazocine and other benzomorphans on σ 1 receptors is also enantioselective. Interestingly, the interaction of PREGS with NMDA and GABA A receptors is not enantioselective in cultured neurons (7, 33) . Since ent-PREGS has been shown to exert either more potent (6) or less potent (7) effects on memory in rodents than PREGS, it would be important to determine if the lack of interaction of ent-PREGS with presynaptic metabotropic σ 1 ↑like receptors contributes to its differential effects in vivo.
Significance:
PREGS modulated glutamate release probability at concentrations ≥10 µM, which appears to be a higher concentration than expected for a physiologically relevant action.
Recent papers reported concentrations of ~8 ng/g of rat brain tissue (2) and ~13 ng/g of rat hippocampal tissue (5) . However, these concentrations of PREGS were determined in homogenates of brain tissue from adult rats and the actual synaptic concentrations of this neurosteroid are unknown. It is entirely possible that PREGS reaches µM levels in synaptic regions under certain conditions. Moreover, PREGS levels could be higher in the immature nervous system where the NMDAR activity is higher than in the mature nervous system.
Indeed, Ca 2+ influx through NMDARs has been shown to stimulate PREGS synthesis in cultured hippocampal neurons (56) and in isolated rat retinas (57) . Thus, we believe that our findings have significant physiological implications. It should also be emphasized that we detected a clear effect of DHEAS at concentrations as low as 0.1 and 1 µM, which also lends support to the physiological relevance of our findings.
In conclusion, we postulate that the effects of PREGS and DHEAS on quantal glutamatergic 
